TULOBUTEROL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C12H18ClNO.ClH
Molecular Weight	264.191
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1

InChI

InChIKey=RSLNRVYIRDVHLY-UHFFFAOYSA-N

InChI=1S/C12H18ClNO.ClH/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13;/h4-7,11,14-15H,8H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C12H18ClNO
Molecular Weight	227.73
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078
Curator's Comment: description was created based on several sources, including: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf

Tulobuterol is a long-acting beta2-adrenergic receptor agonist. Tulobuterol has almost no effects on blood pressure and heart rate and is highly selective for the tracheal muscle. It is indicated to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema. Serious side effects detected were: tremor, palpitations and serum potassium level decrease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15212190	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 50 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 3.68064004E11
Bronchitis 51 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 3.68064004E11
Chronic obstructive pulmonary disease 174 Sources: http://hokunalin.jp/patient/introduction/effect.html	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, COPD or emphysema. Launch Date 3.68064004E11
Emphysema 13 Sources: http://www.mylan.co.jp/-/media/mylanjp/documents/epd_products/20170220%20hokunalin1ds0.1_r7.pdf	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 3.68064004E11

PubMed

Title	Date	PubMed
Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol.	1987 Dec	2893778
Quantitative determination of clenbuterol, salbutamol and tulobuterol enantiomers by capillary electrophoresis.	2001 Feb	11293696
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.	2001 Jan	11201164
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].	2001 Oct	11676124
Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function.	2002 Dec	12390295
[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].	2002 Jan	11828751
Effects of a nitro compound patch on neuropathy in Churg-Strauss syndrome.	2003 Jul	12823139
[Pharmacological action and clinical aspects of salmeterol].	2003 Sep	12939544
Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma.	2004	15212190
Evaluation of MISPE for the multi-residue extraction of beta-agonists from calves urine.	2004 May 5	15093162
Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.	2005	16336029
Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy.	2005	16021849
High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma.	2005 Feb 7	15664761
Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry.	2005 Jan-Feb	15759727
Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry.	2005 Jan-Feb	15759725
Differential effects of short-acting beta2-agonists on human granulocyte functions.	2006	16272820
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.	2006 Jun	16802779
Immunology and homeopathy. 3. Experimental studies on animal models.	2006 Jun	16786046
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.	2006 Sep	16939989
Bioequivalence of marketed transdermal delivery systems for tulobuterol.	2007 Aug	17666825
[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].	2007 Jan	17331388
Transdermal treatment with tulobuterol increases isometric contractile properties of diaphragm muscle in mice.	2007 Jul	17592218
Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.	2007 Mar	17454319
Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch.	2007 Sep	17587559
Characterization of monolithic matrix patch system containing tulobuterol.	2008 Aug	18787793
Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease.	2008 Dec	18983928
[Simultaneous determination of nine beta-agonist residues in animal derived foods by ultra performance liquid chromatography-tandem mass spectrometry].	2008 Nov	19253549
Cough and transdermal long-acting beta2 agonist in Japan.	2008 Oct	18573645
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma.	2009 Dec	19700936
Chronic eosinophilic pneumonia: a case report and review of the literature.	2009 Jul 2	19830005
Detection of tulobuterol crystal in transdermal patches using terahertz pulsed spectroscopy and imaging.	2009 Jun	19618670
Comparison of adherence and efficacy between inhaled salmeterol and transdermal tulobuterol patch in elderly patients with chronic obstructive pulmonary disorder.	2009 May	19470012
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.	2010	20930390
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010 Apr	20155493
Characterization and release behaviors of porous PCL/Eudragit RS microcapsules containing tulobuterol.	2010 Apr 1	20034769
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry].	2010 Aug	21261043
Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD.	2010 Feb	19875277
Effect of porous silica on sustained release behaviors of pH sensitive pluronic F127/poly(acrylic acid) hydrogels containing tulobuterol.	2010 Oct 15	20621457

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults and children aged 9 or older, apply 2 mg of the tape to the chest, back, or upper arm, once daily. For children aged 6 months to 2 years, apply 0.5 mg of the tape to the chest, back, or upper arm, once daily. For children aged 3 to 8 years, apply 1 mg of the tape to the chest, back, or upper arm, once daily. This preparation contains 2 mg of the active ingredients in a piece of tape.

Route of Administration: Transdermal

In Vitro Use Guide

The binding rate of 14 C-tulobuterol hydrochloride to the serum protein (human) was 28.14 ± 1.53% in vitro (Mean ± S.E.).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:44:42 UTC 2023` Edited by `admin` on `Fri Dec 15 16:44:42 UTC 2023`
Record UNII	VNC12181T0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TULOBUTEROL HYDROCHLORIDE

Common Name

English

HOKUNALIN

Brand Name

English

TULOBUTEROL HCL

Common Name

English

TULOBUTEROL HYDROCHLORIDE [MART.]

Common Name

English

BRELOMAX

Brand Name

English

.ALPHA.-((TERT-BUTYLAMINO)METHYL)-O-CHLOROBENZYL ALCOHOL HYDROCHLORIDE

Common Name

English

ATENOS

Brand Name

English

CHLIBAMOL

Brand Name

English

TULOBUTEROL HYDROCHLORIDE [JAN]

Common Name

English

RESPACAL

Brand Name

English

LOBUTEROL

Brand Name

English

BERACHIN

Brand Name

English

BREMAX

Brand Name

English

TULOBUTEROL HYDROCHLORIDE [MI]

Common Name

English

Tulobuterol hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

MERCK INDEX

m11261